Skip to content
Plasma-Safe-SeqS
HNSCC-SEQ

Reliable detection
of clinically relevant
mutations in
HPV-negative HNSCC

HNSCC-SEQ has been designed for HPV-negative HNSCC and can be used to detect novel therapeutic targets and frequently occurring driver mutations for treatment response monitoring. HNSCC-SEQ can also be used for high-sensitivity molecular monitoring to help gauge patients’ response to different therapeutic modalities, with the potential to exceed the resolution offered by current imaging techniques.

Panel features

CLIA-validated, ultra-sensitive blood test for the detection of CDKN2A, EGFR, ERBB2, FGFR3, HRAS, KRAS, NOTCH1, PIK3CA, PTEN, and TP53. This panel detects as few as 8 mutant molecules in a background of 20,000 wild-type molecules (0.04% mutant allele frequency).

GENE GENE REGIONS COVERED (AMINO ACIDS) CLINICAL RELEVANCE
CDKN2A 51-61, 80-91, 96-124, 143-152

Putative therapeutic indication

Marker of poor prognosis

EGFR 283-296, 463-486, 706-725, 856-873 Therapeutic indication
ERBB2 303-315
FGFR3 248-269, 370-392 Putative therapeutic indication
HRAS 9-19, 55-67, 110-123, 144-150

Putative therapeutic indication

Marker of poor prognosis

KRAS 5-26, 141-148, 156-174

Predictive marker for anti-EGFR therapy

Putative therapeutic marker

NOTCH1 184-209, 290-315, 440-468, 562-582, 1836-1862, 1979-1997 Putative therapeutic indication
PICK3CA 72-93, 108-117, 330-352, 354-371, 418-421, 440-462, 538-553, 597-614, 714-728, 970-978, 1001-1025, 1040-1056 Putative therapeutic indication
PTEN 6-26, 87-104, 117-136, 229-247, 329-342 Putative therapeutic indication
TP53 10-24, 26-32, 49-77, 99-125, 126-141, 151-179, 192-219, 233-260, 262-285, 297-306, 308-331, 332-360, 368-383 Truncal mutations important for monitoring
Contact

We’d love to hear from you!

Hidden
Hidden
Hidden
Hidden
Hidden
Hidden